Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16449765 | 0.98 | SIGMAR1 (0.40) | SIGMAR1LMNASMN1; SMN2TERTPOLB | |
| SCHEMBL19601273 | 0.89 | POLB (0.39) | LMNASMN1; SMN2POLBALDH1A1GAA | |
| SCHEMBL16449768 | 0.89 | LMNA (0.36) | LMNASMN1; SMN2POLBALDH1A1TSHR | |
| SCHEMBL835434 | 0.82 | CYP19A1 (0.39) | LMNASMN1; SMN2POLBALDH1A1GAA | |
| SCHEMBL25963873 | 0.82 | KDM1A (0.44) | SIGMAR1LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL25963041 | 0.81 | POLB (0.50) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL13318048 | 0.81 | CYP19A1 (0.46) | SMN1; SMN2POLBALDH1A1GAATSHR | |
| SCHEMBL16675656 | 0.80 | MGLL (0.39) | LMNASMN1; SMN2POLBALDH1A1TP53 | |
| SCHEMBL17190592 | 0.80 | ALDH1A1 (0.39) | SMN1; SMN2POLBALDH1A1GAAPKM | |
| SCHEMBL25010905 | 0.79 | POLB (0.36) | LMNASMN1; SMN2POLBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447136-B2 | Semisynthetic derivatives of Nystatin A1 | BLIRT S.A. (PL) | 2016-09-20 | — | — | US | disclosed |
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | BLIRT S.A. (PL) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045316-A1 | SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1 | NPC1, NPC1L1, LSS | SIGMAR1 1462/4885LMNA 1805/4885SMN1; SMN2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.